Interventional oncologic approaches to liver metastases

Radiology

Volumn 266, Issue 2, 2013, Pages 407-430

  Mahnken, Andreas H ^a   Pereira, Philippe L ^b   De Baère, Thierry ^c  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; CISPLATIN; DEXAMETHASONE; DOXORUBICIN; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IRINOTECAN; MELPHALAN; MICROSPHERE; MITOMYCIN; OXALIPLATIN; PACLITAXEL; TECHNETIUM 99M; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR; YTTRIUM 90;

ARTICLE; ARTIFICIAL EMBOLISM; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CATHETER ABLATION; CHEMOEMBOLIZATION; COLORECTAL CANCER; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG INFUSION; HUMAN; LIVER HYPERTROPHY; LIVER METASTASIS; LIVER RESECTION; MELANOMA; MICROWAVE THERAPY; NEUROENDOCRINE TUMOR; NONHUMAN; OVERALL SURVIVAL; PORTAL VEIN; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RECURRENCE RISK; SALVAGE THERAPY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT INDICATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CATHETER ABLATION; CHEMOEMBOLIZATION, THERAPEUTIC; COLORECTAL NEOPLASMS; EMBOLIZATION, THERAPEUTIC; HUMANS; IMAGING, THREE-DIMENSIONAL; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; PORTAL VEIN; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOGRAPHY, INTERVENTIONAL; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84873376753     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.12112544     Document Type: Article

References (225)

1. Geoghegan JG, Scheele J. Treatment of colorectal liver metastases. Br J Surg 1999;86(2):158-169.
2. Wei AC, Greig PD, Grant D, Taylor B, Langer B, Gallinger S. Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol 2006;13(5):668-676.
3. Gallagher DJ, Kemeny N. Metastatic colorectal cancer: from improved survival to potential cure. Oncology 2010;78(3-4):237-248.
4. Akyildiz H Y, Mitchell J, Milas M, Siperstein A, Berber E. Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up. Surgery 2010;148(6):1288-1293; discussion 1293.
5. Jakobs TF, Hoffmann RT, Schrader A, et al. CT-guided radiofrequency ablation in patients with hepatic metastases from breast cancer. Cardiovasc Intervent Radiol 2009;32(1):38-46.
6. Mack MG, Straub R, Eichler K, Söllner O, Lehnert T, Vogl TJ. Breast cancer metastases in liver: laser-induced interstitial thermotherapy - local tumor control rate and survival data. Radiology 2004;233(2):400-409.
7. Aloia TA, Vauthey JN, Loyer EM, et al. Solitary colorectal liver metastasis: resection determines outcome. Arch Surg 2006;141(5):460-466; discussion 466-467.
8. Minagawa M, Makuuchi M, Torzilli G, et al. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg 2000;231(4):487-499.
9. Elias D, Goere D, Boige V, et al. Outcome of posthepatectomy-missing colorectal liver metastases after complete response to chemotherapy: impact of adjuvant intra-arterial hepatic oxaliplatin. Ann Surg Oncol 2007;14(11):3188- 3194.
10. Madoff DC, Abdalla EK, Vauthey JN. Portal vein embolization in preparation for major hepatic resection: evolution of a new standard of care. J Vasc Interv Radiol 2005;16(6):779-790.
11. Rous P, Larimore LD. Relation of the portal blood to liver maintenance. J Exp Med 1920;31(5):609-632.
12. Starzl TE, Francavilla A, Halgrimson CG, et al. The origin, hormonal nature, and action of hepatotrophic substances in portal venous blood. Surg Gynecol Obstet 1973;137(2):179-199.
13. Zarnegar R, Michalopoulos G. Purification and biological characterization of human hepatopoietin A, a polypeptide growth factor for hepatocytes. Cancer Res 1989;49(12):3314-3320.
14. Lesurtel M, Graf R, Aleil B, et al. Plateletderived serotonin mediates liver regeneration. Science 2006;312(5770):104-107.
15. Kim RD, Kim JS, Watanabe G, Mohuczy D, Behrns KE. Liver regeneration and the atrophy-hypertrophy complex. Semin Intervent Radiol 2008;25(2):92-103.
16. Denys A, Bize P, Demartines N, Deschamps F, De Baere T; Cardiovascular and Interventional Radiological Society of Europe. Quality improvement for portal vein embolization. Cardiovasc Intervent Radiol 2010;33(3):452-456.
17. Johnson TN, Tucker GT, Tanner MS, Rostami-Hodjegan A. Changes in liver volume from birth to adulthood: a meta-analysis. Liver Transpl 2005;11(12):1481-1493.
18. Nagino M, Nimura Y, Kamiya J, Kondo S, Kanai M. Selective percutaneous transhepatic embolization of the portal vein in preparation for extensive liver resection: the ipsilateral approach. Radiology 1996;200(2):559-563.
19. Azoulay D, Castaing D, Krissat J, et al. Percutaneous portal vein embolization increases the feasibility and safety of major liver resection for hepatocellular carcinoma in injured liver. Ann Surg 2000;232(5):665-672.
20. De Baere T, Roche A, Vavasseur D, et al. Portal vein embolization: utility for inducing left hepatic lobe hypertrophy before surgery. Radiology 1993;188(1):73-77.
21. Madoff DC, Hicks ME, Abdalla EK, Morris JS, Vauthey JN. Portal vein embolization with polyvinyl alcohol particles and coils in preparation for major liver resection for hepatobiliary malignancy: safety and effectiveness - study in 26 patients. Radiology 2003;227(1):251-260.
22. Di Stefano DR, De Baère T, Denys A, et al. Preoperative percutaneous portal vein embolization: evaluation of adverse events in 188 patients. Radiology 2005;234(2):625-630.
23. Tsuge H, Mimura H, Kawata N, Orita K. Right portal embolization before extended right hepatectomy using laparoscopic catheterization of the ileocolic vein: a prospective study. Surg Laparosc Endosc 1994;4(4):258-263.
24. Perarnau JM, Daradkeh S, Johann M, Deneuville M, Weinling P, Coniel C. Transjugular preoperative portal embolization (TJPE) a pilot study. Hepatogastroenterology 2003;50(51):610-613.
25. Abdalla EK, Hicks ME, Vauthey JN. Portal vein embolization: rationale, technique and future prospects. Br J Surg 2001;88(2):165-175.
26. De Baere T, Roche A, Elias D, Lasser P, Lagrange C, Bousson V. Preoperative portal vein embolization for extension of hepatectomy indications. Hepatology 1996;24(6):1386-1391.
27. Kinoshita H, Sakai K, Hirohashi K, Igawa S, Yamasaki O, Kubo S. Preoperative portal vein embolization for hepatocellular carcinoma. World J Surg 1986;10(5):803-808.
28. Makuuchi M, Thai BL, Takayasu K, et al. Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. Surgery 1990;107(5):521-527.
29. Matsuoka T. Experimental studies of intrahepatic portal vein embolization and embolic materials [in Japanese]. Nippon Igaku Hoshasen Gakkai Zasshi 1989;49(5):593-606.
30. Yamakado K, Takeda K, Nishide Y, et al. Portal vein embolization with steel coils and absolute ethanol: a comparative experimental study with canine liver. Hepatology 1995;22(6):1812-1818.
31. Denys AL, Abehsera M, Sauvanet A, Sibert A, Belghiti J, Menu Y. Failure of right portal vein ligation to induce left lobe hypertrophy due to intrahepatic portoportal collaterals: successful treatment with portal vein embolization. AJR Am J Roentgenol 1999;173(3):633-635.
32. Madoff DC, Abdalla EK, Gupta S, et al. Transhepatic ipsilateral right portal vein embolization extended to segment IV: improving hypertrophy and resection outcomes with spherical particles and coils. J Vasc Interv Radiol 2005;16(2 Pt 1):215-225.
33. De Baere T, Denys A, Paradis V. Comparison of four embolic materials for portal vein embolization: experimental study in pigs. Eur Radiol 2009;19(6):1435-1442.
34. Tsoumakidou G, Theocharis S, Ptohis N, et al. Liver hypertrophy after percutaneous portal vein embolization: comparison of N-butyl-2-cyanocrylate versus sodium acrylate-vinyl alcohol copolymer particles in a swine model. Cardiovasc Intervent Radiol 2011;34(5):1042-1049.
35. Kishi Y, Madoff DC, Abdalla EK, et al. Is embolization of segment 4 portal veins before extended right hepatectomy justified? Surgery 2008;144(5):744-751.
36. De Baere T, Robinson JM, Deschamps F, et al. Preoperative portal vein embolization tailored to prepare the liver for complex resections: initial experience. Cardiovasc Intervent Radiol 2010;33(5):976-982.
37. Kubota K, Makuuchi M, Kusaka K, et al. Measurement of liver volume and hepatic functional reserve as a guide to decisionmaking in resectional surgery for hepatic tumors. Hepatology 1997;26(5):1176-1181.
38. Corrêa D, Schwartz L, Jarnagin WR, et al. Kinetics of liver volume changes in the first year after portal vein embolization. Arch Surg 2010;145(4):351-354; discussion 354-355.
39. Farges O, Belghiti J, Kianmanesh R, et al. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg 2003;237(2):208-217.
40. De Baere T, Teriitehau C, Deschamps F, et al. Predictive factors for hypertrophy of the future remnant liver after selective portal vein embolization. Ann Surg Oncol 2010;17(8):2081-2089.
41. Denys A, Lacombe C, Schneider F, et al. Portal vein embolization with N-butyl cyanoacrylate before partial hepatectomy in patients with hepatocellular carcinoma and underlying cirrhosis or advanced fibrosis. J Vasc Interv Radiol 2005;16(12):1667-1674.
42. Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004;15(3):460-466.
43. Covey AM, Tuorto S, Brody LA, et al. Safety and efficacy of preoperative portal vein embolization with polyvinyl alcohol in 58 patients with liver metastases. AJR Am J Roentgenol 2005;185(6):1620-1626.
44. Goéré D, Farges O, Leporrier J, Sauvanet A, Vilgrain V, Belghiti J. Chemotherapy does not impair hypertrophy of the left liver after right portal vein obstruction. J Gastrointest Surg 2006;10(3):365-370.
45. Aussilhou B, Dokmak S, Faivre S, Paradis V, Vilgrain V, Belghiti J. Preoperative liver hypertrophy induced by portal fow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab. Ann Surg Oncol 2009;16(6):1553-1559.
46. Zorzi D, Chun YS, Madoff DC, Abdalla EK, Vauthey JN. Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases. Ann Surg Oncol 2008;15(10):2765-2772.
47. Yamakado K, Nakatsuka A, Tanaka N, Matsumura K, Takase K, Takeda K. Longterm follow-up arterial chemoembolization combined with transportal ethanol injection used to treat hepatocellular carcinoma. J Vasc Interv Radiol 1999;10(5):641-647.
48. Ogata S, Belghiti J, Farges O, Varma D, Sibert A, Vilgrain V. Sequential arterial and portal vein embolizations before right hepatectomy in patients with cirrhosis and hepatocellular carcinoma. Br J Surg 2006;93(9):1091-1098.
49. Elias D, De Baere T, Roche A, Mducreux, Leclere J, Lasser P. During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma. Br J Surg 1999;86(6):784-788.
50. Pamecha V, Levene A, Grillo F, Woodward N, Dhillon A, Davidson BR. Effect of portal vein embolisation on the growth rate of colorectal liver metastases. Br J Cancer 2009;100(4):617-622.
51. Elias D, Santoro R, Ouellet JF, Osmak L, De Baere T, Roche A. Simultaneous percutaneous right portal vein embolization and left liver tumor radiofrequency ablation prior to a major right hepatic resection for bilateral colorectal metastases. Hepatogastroenterology 2004;51(60):1788-1791.
52. Azoulay D, Castaing D, Smail A, et al. Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization. Ann Surg 2000;231(4):480-486.
53. Elias D, Ouellet JF, De Baère T, Lasser P, Roche A. Preoperative selective portal vein embolization before hepatectomy for liver metastases: long-term results and impact on survival. Surgery 2002;131(3):294-299.
54. Oussoultzoglou E, Bachellier P, Rosso E, et al. Right portal vein embolization before right hepatectomy for unilobar colorectal liver metastases reduces the intrahepatic recurrence rate. Ann Surg 2006;244(1):71-79.
55. Pamecha V, Glantzounis G, Davies N, Fusai G, Sharma D, Davidson B. Long-term survival and disease recurrence following portal vein embolisation prior to major hepatectomy for colorectal metastases. Ann Surg Oncol 2009;16(5):1202-1207.
56. Elias D, De Baere T, Smayra T, Ouellet JF, Roche A, Lasser P. Percutaneous radiofrequency thermoablation as an alternative to surgery for treatment of liver tumour recurrence after hepatectomy. Br J Surg 2002;89(6):752-756.
57. Van Riel JM, Van Groeningen CJ, Kedde MA, et al. Continuous administration of irinotecan by hepatic arterial infiusion: a phase I and pharmacokinetic study. Clin Cancer Res 2002;8(2):405-412.
58. Dzodic R, Gomez-Abuin G, Rougier P, et al. Pharmacokinetic advantage of intra-arterial hepatic oxaliplatin administration: comparative results with cisplatin using a rabbit VX2 tumor model. Anticancer Drugs 2004;15(6):647-650.
59. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360(6):563-572.
60. Deschamps F, Rao P, Teriitehau C, et al. Percutaneous femoral implantation of an arterial port catheter for intraarterial chemotherapy: feasibility and predictive factors of long-term functionality. J Vasc Interv Radiol 2010;21(11):1681-1688.
61. Tajima T, Yoshimitsu K, Kuroiwa T, et al. Percutaneous femoral catheter placement for long-term chemotherapy infiusions: preliminary technical results. AJR Am J Roentgenol 2005;184(3):906-914.
62. Arai Y, Kamimura N, Suyama K. A method to retain subcutaneously the catheter end connected to a new silicone reservoir in intraarterial infiusion chemotherapy [in Japanese]. Gan To Kagaku Ryoho 1982;9(10):1838-1843.
63. Zanon C, Grosso M, Clara R, et al. Combined regional and systemic chemotherapy by a mini-invasive approach for the treatment of colorectal liver metastases. Am J Clin Oncol 2001;24(4):354-359.
64. Habbe TG, McCowan TC, Goertzen TC, Leveen RF, Culp WC, Tempero MA. Complications and technical limitations of hepatic arterial infiusion catheter placement for chemotherapy. J Vasc Interv Radiol 1998;9(2):233-239.
65. Tanaka T, Arai Y, Inaba Y, et al. Radiologic placement of side-hole catheter with tip fxation for hepatic arterial infiusion chemotherapy. J Vasc Interv Radiol 2003;14(1):63-68.
66. Yamagami T, Nakamura T, Iida S, Kato T, Nishimura T. Embolization of the right gastric artery before hepatic arterial infiusion chemotherapy to prevent gastric mucosal lesions: approach through the hepatic artery versus the left gastric artery. AJR Am J Roentgenol 2002;179(6):1605-1610.
67. Inaba Y, Arai Y, Matsueda K, Takeuchi Y, Aramaki T. Right gastric artery embolization to prevent acute gastric mucosal lesions in patients undergoing repeat hepatic arterial infiusion chemotherapy. J Vasc Interv Radiol 2001;12(8):957-963.
68. Deschamps F, Elias D, Goere D, et al. Intra-arterial hepatic chemotherapy: a comparison of percutaneous versus surgical implantation of port-catheters. Cardiovasc Intervent Radiol 2011;34(5):973-979.
69. Allen-Mersh TG, Earlam S, Fordy C, Abrams K, Houghton J. Quality of life and survival with continuous hepatic-artery foxuridine infusion for colorectal liver metastases. Lancet 1994;344(8932):1255-1260.
70. Rougier P, Laplanche A, Huguier M, et al. Hepatic arterial infusion of foxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 1992;10(7):1112-1118.
71. Kemeny NE, Niedzwiecki D, Hollis DR, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 2006;24(9):1395-1403.
72. Lorenz M, Müller HH. Randomized, multicenter trial of fuorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fuorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol 2000;18(2):243-254.
73. Fiorentini G, Rossi S, Dentico P, et al. Irinotecan hepatic arterial infusion chemotherapy for hepatic metastases from colorectal cancer: a phase II clinical study. Tumori 2003;89(4):382-384.
74. Van Riel JM, Van Groeningen CJ, De Greve J, Gruia G, Pinedo HM, Giaccone G. Continuous infusion of hepatic arterial irinotecan in pretreated patients with colorectal cancer metastatic to the liver. Ann Oncol 2004;15(1):59-63.
75. Boige V, Malka D, Elias D, et al. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol 2008;15(1):219-226.
76. Kemeny NE, Melendez FD, Capanu M, et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2009;27(21):3465-3471.
77. Malka D, Paris E, Caramella C, et al. Combined Hepatic Oxaliplatin, IV LV5FU2 and Erbitux. Proc ASCO 2010 2010: abstr 3558.
78. Livraghi T, Giorgio A, Marin G, et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 1995;197(1):101-108.
79. Ahmed M, Brace CL, Lee FT Jr, Goldberg SN. Principles of and advances in percutaneous ablation. Radiology 2011;258(2):351-369.
80. Livraghi T, Vettori C, Lazzaroni S. Liver metastases: results of percutaneous ethanol injection in 14 patients. Radiology 1991;179(3):709-712.
81. Vogl TJ, Mack MG, Roggan A, et al. Internally cooled power laser for MR-guided interstitial laser-induced thermotherapy of liver lesions: initial clinical results. Radiology 1998;209(2):381-385.
82. Thomson KR, Cheung W, Ellis SJ, et al. Investigation of the safety of irreversible electroporation in humans. J Vasc Interv Radiol 2011;22(5):611-621.
83. Denys AL, De Baere T, Kuoch V, et al. Radio-frequency tissue ablation of the liver: in vivo and ex vivo experiments with four different systems. Eur Radiol 2003;13(10):2346-2352.
84. Lu DS, Raman SS, Limanond P, et al. Influence of large peritumoral vessels on outcome of radiofrequency ablation of liver tumors. J Vasc Interv Radiol 2003;14(10):1267-1274.
85. Goldberg SN, Gazelle GS, Halpern EF, Rittman WJ, Mueller PR, Rosenthal DI. Radiofrequency tissue ablation: importance of local temperature along the electrode tip exposure in determining lesion shape and size. Acad Radiol 1996;3(3):212-218.
86. Gage AA, Baust J. Mechanisms of tissue injury in cryosurgery. Cryobiology 1998;37(3):171-186.
87. Pereira PL, Trübenbach J, Schenk M, et al. Radiofrequency ablation: in vivo comparison of four commercially available devices in pig livers. Radiology 2004;232(2):482-490.
88. Clasen S, Schmidt D, Boss A, et al. Multipolar radiofrequency ablation with internally cooled electrodes: experimental study in ex vivo bovine liver with mathematic modeling. Radiology 2006;238(3):881-890.
89. Brace CL. Radiofrequency and microwave ablation of the liver, lung, kidney, and bone: what are the differences? Curr Probl Diagn Radiol 2009;38(3):135-143.
90. Yu J, Liang P, Yu X, Liu F, Chen L, Wang Y. A comparison of microwave ablation and bipolar radiofrequency ablation both with an internally cooled probe: results in ex vivo and in vivo porcine livers. Eur J Radiol 2011;79(1):124-130.
91. Stuchly MA, Athey T W, Stuchly SS, Samaras GM, Taylor G. Dielectric properties of animal tissues in vivo at frequencies 10 MHz - 1 GHz. Bioelectromagnetics 1981;2(2):93-103.
92. Joines WT, Zhang Y, Li C, Jirtle RL. The measured electrical properties of normal and malignant human tissues from 50 to 900 MHz. Med Phys 1994;21(4):547-550.
93. Kuang M, Lu MD, Xie XY, et al. Liver cancer: increased microwave delivery to ablation zone with cooled-shaft antenna - experimental and clinical studies. Radiology 2007;242(3):914-924.
94. Schramm W, Yang D, Wood BJ, Rattay F, Haemmerich D. Contribution of direct heating, thermal conduction and perfusion during radiofrequency and microwave ablation. Open Biomed Eng J 2007;1:47-52.
95. Wright AS, Lee FT Jr, Mahvi DM. Hepatic microwave ablation with multiple antennae results in synergistically larger zones of coagulation necrosis. Ann Surg Oncol 2003;10(3):275-283.
96. Abitabile P, Hartl U, Lange J, Maurer CA. Radiofrequency ablation permits an effective treatment for colorectal liver metastasis. Eur J Surg Oncol 2007;33(1):67-71.
97. Sgouros J, Cast J, Garadi KK, et al. Chemotherapy plus percutaneous radiofrequency ablation in patients with inoperable colorectal liver metastases. World J Gastrointest Oncol 2011;3(4):60-66.
98. Otto G, Düber C, Hoppe-Lotichius M, König J, Heise M, Pitton MB. Radiofrequency ablation as first-line treatment in patients with early colorectal liver metastases amenable to surgery. Ann Surg 2010;251(5):796-803.
99. Mulier S, Ni Y, Jamart J, Ruers T, Marchal G, Michel L. Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg 2005;242(2):158-171.
100. Hur H, Ko YT, Min BS, et al. Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg 2009;197(6):728-736.
101. Ahmad A, Chen SL, Kavanagh MA, Allegra DP, Bilchik AJ. Radiofrequency ablation of hepatic metastases from colorectal cancer: are newer generation probes better? Am Surg 2006;72(10):875-879.
102. Poon RT, Ng KK, Lam CM, et al. Learning curve for radiofrequency ablation of liver tumors: prospective analysis of initial 100 patients in a tertiary institution. Ann Surg 2004;239(4):441-449.
103. Gillams AR, Lees WR. Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur Radiol 2009;19(5):1206-1213.
104. Siperstein AE, Berber E, Ballem N, Parikh RT. Survival after radiofrequency ablation of colorectal liver metastases:10-year experience. Ann Surg 2007;246(4):559-565; discussion 565-567.
105. Machi J, Oishi AJ, Sumida K, et al. Longterm outcome of radiofrequency ablation for unresectable liver metastases from colorectal cancer: evaluation of prognostic factors and effectiveness in first-and second-line management. Cancer J 2006;12(4):318-326.
106. Vogl TJ, Straub R, Eichler K, Söllner O, Mack MG. Colorectal carcinoma metastases in liver: laser-induced interstitial thermotherapy - local tumor control rate and survival data. Radiology 2004;230(2):450-458.
107. Xu KC, Niu LZ, He WB, Hu YZ, Zuo JS. Percutaneous cryosurgery for the treatment of hepatic colorectal metastases. World J Gastroenterol 2008;14(9):1430-1436.
108. Adam R, Hagopian EJ, Linhares M, et al. A comparison of percutaneous cryosurgery and percutaneous radiofrequency for unresectable hepatic malignancies. Arch Surg 2002;137(12):1332-1339; discussion 1340.
109. Pearson AS, Izzo F, Fleming RY, et al. Intraoperative radiofrequency ablation or cryoablation for hepatic malignancies. Am J Surg 1999;178(6):592-599.
110. Shibata T, Niinobu T, Ogata N, Takami M. Microwave coagulation therapy for multiple hepatic metastases from colorectal carcinoma. Cancer 2000;89(2):276-284.
111. Nicholl MB, Conway WC, Bilchik A, Singh G. Should microwave energy be preferred to radiofrequency energy for ablation of malignant liver tumors? J Interv Oncol 2010;3:12-16.
112. Hompes R, Fieuws S, Aerts R, Thijs M, Penninckx F, Topal B. Results of single-probe microwave ablation of metastatic liver cancer. Eur J Surg Oncol 2010;36(8):725-730.
113. Er O, Frye DK, Kau S-WC, et al. Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy. Cancer J 2008;14(1):62-68.
114. Meloni MF, Andreano A, Laeseke PF, Livraghi T, Sironi S, Lee FT Jr. Breast cancer liver metastases: US-guided percutaneous radiofrequency ablation - intermediate and long-term survival rates. Radiology 2009;253(3):861-869.
115. Sofocleous CT, Nascimento RG, Gonen M, et al. Radiofrequency ablation in the management of liver metastases from breast cancer. AJR Am J Roentgenol 2007;189(4):883-889.
116. Adam R, Aloia T, Krissat J, et al. Is liver resection justified for patients with hepatic metastases from breast cancer? Ann Surg 2006;244(6):897-907; discussion 907-908.
117. Gervais DA, Arellano RS, Mueller PR. Percutaneous radiofrequency ablation of ovarian cancer metastasis to the liver: indications, outcomes, and role in patient management. AJR Am J Roentgenol 2006;187(3):746-750.
118. Kim HR, Cheon SH, Lee KH, et al. Efficacy and feasibility of radiofrequency ablation for liver metastases from gastric adenocarcinoma. Int J Hyperthermia 2010;26(4):305-315.
119. Mylona S, Stroumpouli E, Pomoni M, Galani P, Ntai S, Thanos L. Radiofrequency ablation of liver metastases from cancer of unknown primary site. Diagn Interv Radiol 2009;15(4):297-302.
120. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 2003;197(1):29-37.
121. Cozzi PJ, Englund R, Morris DL. Cryotherapy treatment of patients with hepatic metastases from neuroendocrine tumors. Cancer 1995;76(3):501-509.
122. Gillams A, Cassoni A, Conway G, Lees W. Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience. Abdom Imaging 2005;30(4):435-441.
123. Mazzaglia PJ, Berber E, Milas M, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery 2007;142(1):10-19.
124. El Zouhairi M, Charabaty A, Pishvaian MJ. Molecularly targeted therapy for metastatic colon cancer: proven treatments and promising new agents. Gastrointest Cancer Res 2011;4(1):15-21.
125. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fuorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-2342.
126. Geschwind JF, Kaushik S, Ramsey DE, Choti MA, Fishman EK, Kobeiter H. Influence of a new prophylactic antibiotic therapy on the incidence of liver abscesses after chemoembolization treatment of liver tumors. J Vasc Interv Radiol 2002;13(11):1163-1166.
127. Giammarile F, Bodei L, Chiesa C, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging 2011;38(7):1393-1406.
128. Kennedy A, Nag S, Salem R, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 2007;68(1):13-23.
129. Lewandowski RJ, Thurston KG, Goin JE, et al. 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F]fuorodeoxyglucose positron emission tomography and computed tomographic imaging. J Vasc Interv Radiol 2005;16(12):1641-1651.
130. Luo J, Guo RP, Lai EC, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol 2011;18(2):413-420.
131. Iñarrairaegui M, Thurston KG, Bilbao JI, et al. Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2010;21(8):1205-1212.
132. Martin RC, Robbins K, Tomalty D, et al. Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report. World J Surg Oncol 2009;7:80.
133. Vogl TJ, Mack MG, Balzer JO, et al. Liver metastases: neoadjuvant downsizing with transarterial chemoembolization before laserinduced thermotherapy. Radiology 2003;229(2):457-464.
134. Vogl TJ, Naguib NN, Nour-Eldin NE, et al. Repeated chemoembolization followed by laser-induced thermotherapy for liver metastasis of breast cancer. AJR Am J Roentgenol 2011;196(1):W66-W72.
135. Aliberti C, Fiorentini G, Muzzio PC, et al. Trans-arterial chemoembolization of metastatic colorectal carcinoma to the liver adopting DC Bead®, drug-eluting bead loaded with irinotecan: results of a phase II clinical study. Anticancer Res 2011;31(12):4581-4587.
136. Vogl TJ, Gruber T, Balzer JO, Eichler K, Hammerstingl R, Zangos S. Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study. Radiology 2009;250(1):281-289.
137. Van Den Eynde M, Flamen P, El Nakadi I, et al. Inducing resectability of chemotherapy refractory colorectal liver metastasis by radioembolization with yttrium-90 microspheres. Clin Nucl Med 2008;33(10):697-699.
138. Brown DB, Cardella JF, Sacks D, et al. Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol 2009;20(7 Suppl):S219-S226, S226.e1-e10.
139. Lewandowski RJ, Geschwind JF, Liapi E, Salem R. Transcatheter intraarterial therapies: rationale and overview. Radiology 2011;259(3):641-657.
140. Lang EK, Brown CL Jr. Colorectal metastases to the liver: selective chemoembolization. Radiology 1993;189(2):417-422.
141. Martinelli DJ, Wadler S, Bakal CW, et al. Utility of embolization or chemoembolization as second-line treatment in patients with advanced or recurrent colorectal carcinoma. Cancer 1994;74(6):1706-1712.
142. Leichman CG, Jacobson JR, Modiano M, et al. Hepatic chemoembolization combined with systemic infusion of 5-fuorouracil and bolus leucovorin for patients with metastatic colorectal carcinoma: A Southwest Oncology Group pilot trial. Cancer 1999;86(5):775-781.
143. Popov I, Lavrnic S, Jelic S, Jezdic S, Jasovic A. Chemoembolization for liver metastases from colorectal carcinoma: risk or a beneft. Neoplasma 2002;49(1):43-48.
144. Martin RC, Joshi J, Robbins K, et al. Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann Surg Oncol 2011;18(1):192-198.
145. Fiorentini G, Aliberti C, Tilli M, et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res 2012;32(4):1387-1395.
146. Pons F, Plana M, Caminal JM, et al. Metastatic uveal melanoma: is there a role for conventional chemotherapy? - A single center study based on 58 patients. Melanoma Res 2011;21(3):217-222.
147. Gonsalves CF, Eschelman DJ, Sullivan KL, Anne PR, Doyle L, Sato T. Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single-institution experience. AJR Am J Roentgenol 2011;196(2):468-473.
148. Kennedy AS, Nutting C, Jakobs T, et al. A first report of radioembolization for hepatic metastases from ocular melanoma. Cancer Invest 2009;27(6):682-690.
149. Kress O, Wagner HJ, Wied M, Klose KJ, Arnold R, Alfke H. Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors - a retrospective single-center analysis. Digestion 2003;68(2-3):94-101.
150. Chung J W, Park JH, Han JK, et al. Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology 1996;198(1):33-40.
151. Yu JS, Kim KW, Jeong MG, Lee DH, Park MS, Yoon S W. Predisposing factors of bile duct injury after transcatheter arterial chemoembolization (TACE) for hepatic malignancy. Cardiovasc Intervent Radiol 2002;25(4):270-274.
152. Russell AH, Clyde C, Wasserman TH, Turner SS, Rotman M. Accelerated hyperfractionated hepatic irradiation in the management of patients with liver metastases: results of the RTOG dose escalating protocol. Int J Radiat Oncol Biol Phys 1993;27(1):117-123.
153. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21(1):109-122.
154. Dawson LA, McGinn CJ, Normolle D, et al. Escalated focal liver radiation and concurrent hepatic artery fuorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol 2000;18(11):2210-2218.
155. Dawson LA, Normolle D, Balter JM, Mc-Ginn CJ, Lawrence TS, Ten Haken RK. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 2002;53(4):810-821.
156. Blanchard RJ, Lafave J W, Kim YS, Frye CS, Ritchie WP, Perry JF Jr. Treatment of patients with advanced cancer using Y-90 microspheres. Cancer 1965;18:375-380.
157. Ariel IM, Padula G. Treatment of symptomatic metastatic cancer to the liver from primary colon and rectal cancer by the intraarterial administration of chemotherapy and radioactive isotopes. J Surg Oncol 1978;10(4):327-336.
158. Mantravadi RV, Spigos DG, Tan WS, Felix EL. Intraarterial yttrium 90 in the treatment of hepatic malignancy. Radiology 1982;142(3):783-786.
159. Shepherd FA, Rotstein LE, Houle S, Yip TC, Paul K, Sniderman K W. A phase I dose escalation trial of yttrium-90 microspheres in the treatment of primary hepatocellular carcinoma. Cancer 1992;70(9):2250-2254.
160. Wollner I, Knutsen C, Smith P, et al. Effects of hepatic arterial yttrium 90 glass microspheres in dogs. Cancer 1988;61(7):1336-1344.
161. Lau WY, Leung WT, Ho S, et al. Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. Br J Cancer 1994;70(5):994-999.
162. Campbell AM, Bailey IH, Burton MA. Tumour dosimetry in human liver following hepatic yttrium-90 microsphere therapy. Phys Med Biol 2001;46(2):487-498.
163. Sarfaraz M, Kennedy AS, Lodge MA, Li XA, Wu X, Yu CX. Radiation absorbed dose distribution in a patient treated with yttrium-90 microspheres for hepatocellular carcinoma. Med Phys 2004;31(9):2449-2453.
164. Liu DM, Salem R, Bui JT, et al. Angiographic considerations in patients undergoing liver-directed therapy. J Vasc Interv Radiol 2005;16(7):911-935.
165. Ahmadzadehfar H, Sabet A, Biermann K, et al. The significance of 99mTc-MAA SPECT/CT liver perfusion imaging in treatment planning for 90Y-microsphere selective internal radiation treatment. J Nucl Med 2010;51(8):1206-1212.
166. Gray B, Van Hazel G, Hope M, et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 2001;12(12):1711-1720.
167. Van Hazel G, Blackwell A, Anderson J, et al. Randomised phase 2 trial of SIR-Spheres plus fuorouracil/leucovorin chemotherapy versus fuorouracil/ leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 2004;88(2):78-85.
168. Hendlisz A, Van Den Eynde M, Peeters M, et al. Phase III trial comparing protracted intravenous fuorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 2010;28(23):3687-3694.
169. Vente MA, Wondergem M, Van der Tweel I, et al. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. Eur Radiol 2009;19(4):951-959.
170. Poggi G, Pozzi E, Riccardi A, et al. Complications of image-guided transcatheter hepatic chemoembolization of primary and secondary tumours of the liver. Anticancer Res 2010;30(12):5159-5164.
171. Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer timeto-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011;140(2):497-507, e2.
172. Riaz A, Lewandowski RJ, Kulik LM, et al. Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. J Vasc Interv Radiol 2009;20(9):1121-1130; quiz 1131.
173. Leung TW, Lau WY, Ho SK, et al. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys 1995;33(4):919-924.
174. Salem R, Parikh P, Atassi B, et al. Incidence of radiation pneumonitis after hepatic intraarterial radiotherapy with yttrium-90 microspheres assuming uniform lung dis tribution. Am J Clin Oncol 2008;31(5):431-438.
175. Kennedy AS, McNeillie P, Dezarn WA, et al. Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys 2009;74(5):1494-1500.
176. Sangro B, Gil-Alzugaray B, Rodriguez J, et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer 2008;112(7):1538-1546.
177. Kim YI, Chung JW, Park JH, Han JK, Hong JW, Chung H. Intraarterial gene delivery in rabbit hepatic tumors: transfection with nonviral vector by using iodized oil emulsion. Radiology 2006;240(3):771-777.
178. Fürst G, Schulte Am Esch J, Poll LW, et al. Portal vein embolization and autologous CD1331 bone marrow stem cells for liver regeneration: initial experience. Radiology 2007;243(1):171-179.
179. Liapi E, Geschwind J-FH, Vali M, et al. Assessment of tumoricidal efficacy and response to treatment with 18F-FDG PET/CT after intraarterial infusion with the antiglycolytic agent 3-bromopyruvate in the VX2 model of liver tumor. J Nucl Med 2011;52(2):225-230.
180. Reid T, Galanis E, Abbruzzese J, et al. Intraarterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther 2001;8(21):1618-1626.
181. Srivastava PK. Hypothesis: controlled necrosis as a tool for immunotherapy of human cancer. Cancer Immun 2003;3:4.
182. Haen SP, Gouttefangeas C, Schmidt D, et al. Elevated serum levels of heat shock protein 70 can be detected after radiofrequency ablation. Cell Stress Chaperones 2011;16(5):495-504.
183. Ito A, Honda H, Kobayashi T. Cancer immunotherapy based on intracellular hyperthermia using magnetite nanoparticles: a novel concept of "heat-controlled necrosis" with heat shock protein expression. Cancer Immunol Immunother 2006;55(3):320-328.
184. Vali M, Liapi E, Kowalski J, et al. Intraarterial therapy with a new potent inhibitor of tumor metabolism (3-bromopyruvate): identification of therapeutic dose and method of injection in an animal model of liver cancer. J Vasc Interv Radiol 2007;18(1 Pt 1):95-101.
185. Van Duijnhoven FH, Jansen MC, Junggeburt JM, et al. Factors influencing the local failure rate of radiofrequency ablation of colorectal liver metastases. Ann Surg Oncol 2006;13(5):651-658.
186. Jakobs TF, Hoffmann RT, Trumm C, Reiser MF, Helmberger TK. Radiofrequency ablation of colorectal liver metastases: midterm results in 68 patients. Anticancer Res 2006;26(1 B):671-680.
187. Sørensen SM, Mortensen FV, Nielsen DT. Radiofrequency ablation of colorectal liver metastases: long-term survival. Acta Radiol 2007;48(3):253-258.
188. Veltri A, Sacchetto P, Tosetti I, Pagano E, Fava C, Gandini G. Radiofrequency ablation of colorectal liver metastases: small size favorably predicts technique effectiveness and survival. Cardiovasc Intervent Radiol 2008;31(5):948-956.
189. Bageacu S, Kaczmarek D, Lacroix M, Dubois J, Forest J, Porcheron J. Cryosurgery for resectable and unresectable hepatic metastases from colorectal cancer. Eur J Surg Oncol 2007;33(5):590-596.
190. Pawlik TM, Vauthey JN, Abdalla EK, Pollock RE, Ellis LM, Curley SA. Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver. Arch Surg 2006;141(6):537-543; discussion 543-544.
191. White RR, Avital I, Sofocleous CT, et al. Rates and patterns of recurrence for percutaneous radiofrequency ablation and open wedge resection for solitary colorectal liver metastasis. J Gastrointest Surg 2007;11(3):256-263.
192. Park IJ, Kim HC, Yu CS, Kim PN, Won HJ, Kim JC. Radiofrequency ablation for metachronous liver metastasis from colorectal cancer after curative surgery. Ann Surg Oncol 2008;15(1):227-232.
193. Leblanc F, Fonck M, Brunet R, Becouarn Y, Mathoulin-Pélissier S, Evrard S. Comparison of hepatic recurrences after resection or intraoperative radiofrequency ablation indicated by size and topographical characteristics of the metastases. Eur J Surg Oncol 2008;34(2):185-190.
194. Berber E, Tsinberg M, Tellioglu G, Simpfendorfer CH, Siperstein AE. Resection versus laparoscopic radiofrequency thermal ablation of solitary colorectal liver metastasis. J Gastrointest Surg 2008;12(11):1967-1972.
195. Lee WS, Yun SH, Chun HK, et al. Clinical outcomes of hepatic resection and radiofrequency ablation in patients with solitary colorectal liver metastasis. J Clin Gastroenterol 2008;42(8):945-949.
196. Reuter NP, Woodall CE, Scoggins CR, McMasters KM, Martin RC. Radiofrequency ablation vs. resection for hepatic colorectal metastasis: therapeutically equivalent? J Gastrointest Surg 2009;13(3):486-491.
197. McKay A, Fradette K, Lipschitz J. Longterm outcomes following hepatic resection and radiofrequency ablation of colorectal liver metastases. HPB Surg 2009;2009:346863.
198. Schiffman SC, Bower M, Brown RE, Martin RC, McMasters KM, Scoggins CR. Hepatectomy is superior to thermal ablation for patients with a solitary colorectal liver metastasis. J Gastrointest Surg 2010;14(12):1881-1886; discussion 1886-1887.
199. Müller H, Nakchbandi V, Chatzisavvidis I, Von Voigt C. Repetitive chemoembolization with melphalan plus intra-arterial immunochemotherapy within 5-fuorouracil and granulocyte-macrophage colony-stimulating factor (GM-CSF) as effective first-and second-line treatment of disseminated colorectal liver metastases. Hepatogastroenterology 2003;50(54):1919-1926.
200. Pohlen U, Mansmann U, Berger G, et al. Multicenter pilot study of 5-fuorouracil, folinic acid, interferon alpha-2b and degradable starch microspheres via hepatic arterial infusion in patients with nonresectable colorectal liver metastases. Anticancer Res 2004;24(5 B):3275-3282.
201. Albert M, Kiefer M V, Sun W, et al. Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol. Cancer 2011;117(2):343-352.
202. Gupta S, Johnson MM, Murthy R, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 2005;104(8):1590-1602.
203. Christante D, Pommier S, Givi B, Pommier R. Hepatic artery chemoinfusion with chemoembolization for neuroendocrine cancer with progressive hepatic metastases despite octreotide therapy. Surgery 2008;144(6):885-893; discussion 893-894.
204. Vogl T, Eichler K, Zangos S, et al. Preliminary experience with transarterial chemoembolization (TACE) in liver metastases of uveal malignant melanoma: local tumor control and survival. J Cancer Res Clin Oncol 2007;133(3):177-184.
205. Huppert PE, Fierlbeck G, Pereira P, et al. Transarterial chemoembolization of liver metastases in patients with uveal melanoma. Eur J Radiol 2010;74(3):e38-e44.
206. Vogl TJ, Naguib NN, Nour-Eldin N-EA, Eichler K, Zangos S, Gruber-Rouh T. Transarterial chemoembolization (TACE) with mitomycin C and gemcitabine for liver metastases in breast cancer. Eur Radiol 2010;20(1):173-180.
207. Lim L, Gibbs P, Yip D, et al. A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy. BMC Cancer 2005;5:132.
208. Mancini R, Carpanese L, Sciuto R, et al. A multicentric phase II clinical trial on intraarterial hepatic radiotherapy with 90yttrium SIR-spheres in unresectable, colorectal liver metastases refractory to i.v. chemotherapy: preliminary results on toxicity and response rates. In Vivo 2006;20(6 A):711-714.
209. Kennedy AS, Coldwell D, Nutting C, et al. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys 2006;65(2):412-425.
210. Stubbs RS, O'Brien I, Correia MM. Selective internal radiation therapy with 90Y microspheres for colorectal liver metastases: single-centre experience with 100 patients. ANZ J Surg 2006;76(8):696-703.
211. Jakobs TF, Hoffmann RT, Dehm K, et al. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases. J Vasc Interv Radiol 2008;19(8):1187-1195.
212. Cianni R, Urigo C, Notarianni E, et al. Selective internal radiation therapy with SIR-spheres for the treatment of unresectable colorectal hepatic metastases. Cardiovasc Intervent Radiol 2009;32(6):1179-1186.
213. Van Hazel GA, Pavlakis N, Goldstein D, et al. Treatment of fuorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. J Clin Oncol 2009;27(25):4089-4095.
214. Mulcahy MF, Lewandowski RJ, Ibrahim SM, et al. Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer 2009;115(9):1849-1858.
215. Cosimelli M, Golferi R, Cagol P P, et al. Multicentre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer 2010;103(3):324-331.
216. Evans KA, Richardson MG, Pavlakis N, Morris DL, Liauw W, Bester L. Survival outcomes of a salvage patient population after radioembolization of hepatic metastases with yttrium-90 microspheres. J Vasc Interv Radiol 2010;21(10):1521-1526.
217. Chua TC, Bester L, Saxena A, Morris DL. Radioembolization and systemic chemotherapy improves response and survival for unresectable colorectal liver metastases. J Cancer Res Clin Oncol 2011;137(5):865-873.
218. Rhee TK, Lewandowski RJ, Liu DM, et al. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg 2008;247(6):1029-1035.
219. Kennedy AS, Dezarn WA, McNeillie P, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 2008;31(3):271-279.
220. King J, Quinn R, Glenn DM, et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 2008;113(5):921-929.
221. Saxena A, Chua TC, Bester L, Kokandi A, Morris DL. Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases. Ann Surg 2010;251(5):910-916.
222. Cao CQ, Yan TD, Bester L, Liauw W, Morris DL. Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases. Br J Surg 2010;97(4):537-543.
223. Jakobs TF, Hoffmann RT, Fischer T, et al. Radioembolization in patients with hepatic metastases from breast cancer. J Vasc Interv Radiol 2008;19(5):683-690.
224. Coldwell DM, Kennedy AS, Nutting CW. Use of yttrium-90 microspheres in the treatment of unresectable hepatic metastases from breast cancer. Int J Radiat Oncol Biol Phys 2007;69(3):800-804.
225. Bangash AK, Atassi B, Kaklamani V, et al. 90Y radioembolization of metastatic breast cancer to the liver: toxicity, imaging response, survival. J Vasc Interv Radiol 2007;18(5):621-628.